Get the Stockscreener App
2.17
11.28%
0.22
After Hours:
2.16
-0.010
-0.46%
Serina Therapeutics Inc stock is traded at $2.17, with a volume of 99,531.
It is up +11.28% in the last 24 hours and up +15.43% over the past month.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.
See More
Previous Close:
$1.95
Open:
$1.93
24h Volume:
99,531
Relative Volume:
0.84
Market Cap:
$32.54M
Revenue:
$130.00K
Net Income/Loss:
$-21.29M
P/E Ratio:
-1.0976
EPS:
-1.977
Net Cash Flow:
$-18.29M
1W Performance:
+11.86%
1M Performance:
+15.43%
6M Performance:
-10.33%
1Y Performance:
-60.90%
1-Day Range:
$1.93
$2.2799
1-Week Range:
$1.8808
$2.2799
52-Week Range:
$1.22
$7.92
Serina Therapeutics Inc Stock (SER) Company Profile
Name
Serina Therapeutics Inc
Sector
Industry
Phone
(256) 327-9630
Address
601 GENOME WAY, HUNTSVILLE
Compare SER vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SER
Serina Therapeutics Inc
|
2.17 | 29.25M | 130.00K | -21.29M | -18.29M | -1.977 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Serina Therapeutics Inc Stock (SER) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-14-25 | Initiated | H.C. Wainwright | Buy |
Serina Therapeutics Inc Stock (SER) Latest News
Enterprise value to EBIT forward of Serina Therapeutics, Inc. – AMEX:SER - TradingView
Serina Therapeutics (SER) Stock Forecast and Price Target 2026 $SER - MarketBeat
SER Initiated Coverage by BTIG -- Rating Set to Buy with $8.00 P - GuruFocus
Serina Therapeutics Price Target Announced at $8.00/Share by BTIG - Moomoo
BTIG Initiates Serina Therapeutics(SER.US) With Buy Rating, Announces Target Price $8 - Moomoo
BTIG initiates Serina Therapeutics stock with buy on drug delivery platform - Investing.com Canada
Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program - marketscreener.com
Enterprise value to EBITDA forward of Serina Therapeutics, Inc. – AMEX:SER - TradingView
Enterprise value to revenue forward of Serina Therapeutics, Inc. – AMEX:SER - TradingView
Price to sales forward of Serina Therapeutics, Inc. – AMEX:SER - TradingView
Number of shareholders of Serina Therapeutics, Inc. – AMEX:SER - TradingView
Serina Therapeutics, Inc. Actuals & Estimates (AMEX:SER) - TradingView
SER Forecast — Price Target — Prediction for 2027 - TradingView
2BO Forecast — Price Target — Prediction for 2027 - TradingView
Serina Therapeutics, Inc. Actuals & Estimates (BOATS:SER) - TradingView
Serina Therapeutics Shareholders Approve Expanded Equity and Governance - TipRanks
Serina Therapeutics (NYSE: SER) holders back major share and equity plan increases - Stock Titan
Form 4 Serina Therapeutics Inc For: 22 June By Investing.com - Investing.com South Africa
Serina Therapeutics director Jay Venkatesan buys $1,048 in common stock By Investing.com - Investing.com Australia
Serina Therapeutics director Jay Venkatesan buys $1,048 in common stock - Investing.com
Serina (SER) director converts preferred into common and buys more stock - Stock Titan
Serina Therapeutics (SER) director boosts equity via conversions and new warrants - Stock Titan
Serina Therapeutics (SER) director receives 15,250 stock options at $1.98 - Stock Titan
Serina Therapeutics (SER) director granted 15,250 stock options at $1.98 strike - Stock Titan
Serina Therapeutics (SER) Stock Price, News & Analysis $SER - MarketBeat
Serina Therapeutics Inc (SER) Valuation: PE, PB & Fair Value Analysis - TradingKey
Why Did Serina Therapeutics Stock Rocket 37% After The Bell Today? - MSN
Serina Therapeutics Inc (SER) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Serina Therapeutics Inc (SER) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Serina Therapeutics Inc (SER) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Serina Therapeutics Inc (SER) Institutional Confidence - TradingKey
Serina Therapeutics Inc (SER) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SER: All proposals, including director elections and share increase, were approved without stockholder questions - TradingView
SER: All eight proposals, including board elections and share increase, were approved without stockholder questions - TradingView
Serina Therapeutics Inc (SER) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Serina Therapeutics Inc (SER) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Serina Therapeutics Inc (SER) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
$Serina Therapeutics (SER.US)$ patiently waiting! - Moomoo
Insider Buying: Karen Wilson Acquires Shares of Serina Therapeutics Inc (SER) - GuruFocus
Serina Therapeutics director Karen Wilson buys $17,749 common stock By Investing.com - Investing.com India
Serina Therapeutics director Karen Wilson buys $17,749 common stock - Investing.com UK
Director Karen J. Wilson boosts Serina (SER) stake with 10,100-share purchase - Stock Titan
Serina Therapeutics Inc. (SER) Q1 2026 Earnings: Losses Wider Than Expected as Pre-Revenue Biotech Continues Clinical DevelopmentDownward Estimate Revision - newsline.com
Serina Therapeutics, Inc. Financial Disclosures & SEC Filings - TradingView
Serina Therapeutics (SER) Gains 4% as It Tests Key Resistance at $1.90BPI Bull Confirmed - newsline.com
Serina Therapeutics (SER) Tests Key Support After Modest DeclineSafe Entry Stocks - newsline.com
SER Q1 2026 Earnings: EPS Misses Estimates as Development-Focused Biotechnology Firm Continues Pipeline ProgressGuidance Accuracy Score - dars.gov.et
SER News | SERINA THERAPEUTICS INC. (NYSEARCA:SER) - ChartMill
[EFFECT] Serina Therapeutics, Inc. SEC Filing - Stock Titan
Serina Therapeutics Inc Stock (SER) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.17%
2.48%
Cap:
|
Volume (24h):